Form 4: 60 Degrees Pharmaceuticals CEO Increases Stake Following Reverse Stock Split

Geoffrey S. Dow, President and CEO of 60 Degrees Pharmaceuticals, Inc., acquired additional common stock, bringing his direct and indirect beneficial ownership to 37,290 shares after a recent 1-for-5 reverse stock split.

Summary

• Geoffrey S. Dow, President and CEO, and a Director of 60 Degrees Pharmaceuticals, Inc. (SXTP), reported changes in his beneficial ownership.
• On June 9, 2025, Mr. Dow acquired 4,376 shares of common stock at a price of $2.9855 per share.
• Following this transaction, Mr. Dow directly beneficially owns 26,171 shares of common stock.
• Additionally, Mr. Dow indirectly beneficially owns 11,119 shares through the Geoffrey S. Dow Revocable Trust, for which he serves as trustee with voting and dispositive control.
• The reported share amounts reflect a 1-for-5 reverse stock split that became effective on February 24, 2025.
• As a result of the reverse stock split, Mr. Dow's direct beneficial ownership was adjusted from 108,974 shares to 21,795 shares, and his indirect beneficial ownership was adjusted from 55,596 shares to 11,119 shares.
• Fractional shares resulting from the reverse stock split were rounded up to the nearest whole share.

Sentiment

Score: 6

Explanation: The sentiment is mixed; while the insider acquisition is a positive signal of confidence, the preceding reverse stock split can be perceived negatively as it often indicates efforts to address a low stock price or maintain listing compliance.

Positives

• The acquisition of 4,376 shares by the President and CEO, Geoffrey S. Dow, indicates management's confidence in the company's future prospects.

Negatives

• The 1-for-5 reverse stock split, effective February 24, 2025, often signals a company's efforts to increase its share price, potentially to meet exchange listing requirements or improve market perception, which can sometimes be viewed negatively by investors as it may reflect underlying challenges with stock valuation or performance.

Future Outlook

The document does not provide any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This Form 4 filing reports an insider transaction and the impact of a reverse stock split, which are internal corporate actions. The document does not provide sufficient information to analyze broader industry trends or competitive landscape within the pharmaceutical sector.

Related Party Transactions

• Geoffrey S. Dow's indirect beneficial ownership of 11,119 shares is held through the Geoffrey S. Dow Revocable Trust, of which he is the trustee and has voting and dispositive control.

Stakeholder Impact

• Shareholders are directly impacted by the reverse stock split, which reduced the number of outstanding shares and increased the per-share price, and by the insider's acquisition, which may signal management's belief in future value.

Key Dates

Keywords

60 Degrees Pharmaceuticals, SXTP, Form 4, Insider Trading, Stock Acquisition, Reverse Stock Split, Geoffrey S. Dow, CEO, Director, Beneficial Ownership, Pharmaceuticals